ISBN: 9783642282966
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as â??che… Mehr…
Springer.com new in stock. Versandkosten:zzgl. Versandkosten. (EUR 0.00) Details... |
ISBN: 9783642282966
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemo… Mehr…
Springer.com new in stock. Versandkosten:zzgl. Versandkosten. Details... |
ISBN: 9783642282966
; PDF; Scientific, Technical and Medical > Clinical & internal medicine > Diseases & disorders > Oncology, Gabler Verlag
hive.co.uk No. 9783642282966. Versandkosten:Instock, Despatched same working day before 3pm, zzgl. Versandkosten. Details... |
2012, ISBN: 9783642282966
[ED: 1], Auflage, eBook Download (PDF), eBooks, [PU: Springer-Verlag]
lehmanns.de Versandkosten:Download sofort lieferbar, , Versandkostenfrei innerhalb der BRD (EUR 0.00) Details... |
2012, ISBN: 9783642282966
2012, eBook Download (PDF), eBooks, [PU: Springer Berlin]
lehmanns.de Versandkosten:Download sofort lieferbar, , Versandkostenfrei innerhalb der BRD. (EUR 0.00) Details... |
ISBN: 9783642282966
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as â??che… Mehr…
ISBN: 9783642282966
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemo… Mehr…
ISBN: 9783642282966
; PDF; Scientific, Technical and Medical > Clinical & internal medicine > Diseases & disorders > Oncology, Gabler Verlag
2012, ISBN: 9783642282966
[ED: 1], Auflage, eBook Download (PDF), eBooks, [PU: Springer-Verlag]
2012, ISBN: 9783642282966
2012, eBook Download (PDF), eBooks, [PU: Springer Berlin]
Bibliographische Daten des bestpassenden Buches
Autor: | |
Titel: | |
ISBN-Nummer: |
Detailangaben zum Buch - Therapeutic Kinase Inhibitors
EAN (ISBN-13): 9783642282966
ISBN (ISBN-10): 3642282962
Erscheinungsjahr: 2012
Herausgeber: Springer Berlin
234 Seiten
Sprache: eng/Englisch
Buch in der Datenbank seit 2012-12-03T21:22:03+01:00 (Berlin)
Detailseite zuletzt geändert am 2023-10-25T14:54:19+02:00 (Berlin)
ISBN/EAN: 9783642282966
ISBN - alternative Schreibweisen:
3-642-28296-2, 978-3-642-28296-6
Alternative Schreibweisen und verwandte Suchbegriffe:
Autor des Buches: sawyer, mell, mellin, melling, grabinski
Titel des Buches: kina kina
Daten vom Verlag:
Autor/in: Ingo K. Mellinghoff; Charles L. Sawyers
Titel: Current Topics in Microbiology and Immunology; Therapeutic Kinase Inhibitors
Verlag: Springer; Springer Berlin
234 Seiten
Erscheinungsjahr: 2012-11-27
Berlin; Heidelberg; DE
Sprache: Englisch
149,79 € (DE)
154,00 € (AT)
177,00 CHF (CH)
Available
X, 234 p.
EA; E107; eBook; Nonbooks, PBS / Medizin/Nichtklinische Fächer; Onkologie; Verstehen; Mitogen Activated Protein Kinase (MAPK); Raf kinases; biomarkers; chemical library; clinical trial design; drug development; drug efficacy; epigenetics; gastrointestinal stromal tumor (GIST); genetically engineered mouse models (GEMMs); glioblastoma; lung adenocarcinoma; lung cancer; melanoma; myeloproliferative neoplasms; small molecules; B; Cancer Biology; Biomedical and Life Sciences; BB
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert.
Includes supplementary material: sn.pub/extras
Weitere, andere Bücher, die diesem Buch sehr ähnlich sein könnten:
Neuestes ähnliches Buch:
9783642445804 Therapeutic Kinase Inhibitors (Sawyers, Charles L. (Herausgeber); Mellinghoff, Ingo K. (Herausgeber))
< zum Archiv...